{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:19:17Z","timestamp":1790727557567,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jctube.2021.100216","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T17:04:26Z","timestamp":1610471066000},"page":"100216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California"],"prefix":"10.1016","volume":"23","author":[{"given":"Shereen","family":"Katrak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Lowenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"True","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pennan","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jctube.2021.100216_b0005","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jctube.2021.100216_b0010","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An Official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jctube.2021.100216_b0015","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. 2019 Available at: https:\/\/www.who.int\/tb\/publications\/2019\/consolidated-guidelines-drug-resistant-TB-treatment\/en\/."},{"key":"10.1016\/j.jctube.2021.100216_b0020","unstructured":"TB Elimination. Treatment of Multidrug-Resistant Tuberculosis: Bedaquiline. National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination. Available at; https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/treatment\/Multidrug-Resistant_Tuberculosis_Bedaquiline.pdf."},{"key":"10.1016\/j.jctube.2021.100216_b0025","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","volume":"15","author":"Al-Khatib","year":"2018","journal-title":"Heart Rhythm"},{"issue":"9","key":"10.1016\/j.jctube.2021.100216_b0030","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"55","author":"Drew","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jctube.2021.100216_b0035","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/01.md.0000085057.63483.9b","article-title":"Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors","volume":"82","author":"Zeltser","year":"2003","journal-title":"Medicine"},{"key":"10.1016\/j.jctube.2021.100216_b0040","unstructured":"Mbuagbaw L. Review of available evidence on the use of bedaquiline for the treatment of multidrug-resistant tuberculosis: Data analysis report. Organization TWH. March 8, 2017 Available at: https:\/\/www.who.int\/tb\/publications\/2017\/Appendix_GDGReport_Bedaquiline.pdf."},{"key":"10.1016\/j.jctube.2021.100216_b0045","unstructured":"TB in California: 2018 Snapshot. California Department of Public Health, Tuberculosis Control Branch. 2019 Available at; https:\/\/www.cdph.ca.gov\/Programs\/CID\/DCDC\/CDPH%20Document%20Library\/TBCB-TB-Fact-Sheet-2018.pdf."},{"issue":"1","key":"10.1016\/j.jctube.2021.100216_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5588\/pha.17.0091","article-title":"The California Multidrug-Resistant Tuberculosis Consult Service: a partnership of state and local programs","volume":"8","author":"Shah","year":"2018","journal-title":"Public Health Action"},{"key":"10.1016\/j.jctube.2021.100216_b0055","unstructured":"Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. 2014 Available at: https:\/\/www.who.int\/tb\/publications\/pmdt_companionhandbook\/en\/."},{"issue":"5","key":"10.1016\/j.jctube.2021.100216_b0060","doi-asserted-by":"crossref","first-page":"e0196763","DOI":"10.1371\/journal.pone.0196763","article-title":"Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer","volume":"13","author":"Veronese","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jctube.2021.100216_b0065","doi-asserted-by":"crossref","unstructured":"Li K, Vo K, Lee BK, Addo N, Coralic Z. Effect of a single dose of i.v. ondansetron on QTc interval in emergency department patients. Am J Health-System Pharm AJHP 2018; 75:276\u201382.","DOI":"10.2146\/ajhp161070"},{"key":"10.1016\/j.jctube.2021.100216_b0070","unstructured":"Conradie F HP, Everitt D, et al. Sustained high rate of successful treatment outcomes: Interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid. The Union World Conference on Lung Health, The Hague, Netherlands; 2018."},{"issue":"2","key":"10.1016\/j.jctube.2021.100216_b0075","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jctube.2021.100216_b0080","doi-asserted-by":"crossref","first-page":"1701462","DOI":"10.1183\/13993003.01462-2017","article-title":"Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence","volume":"50","author":"Pontali","year":"2017","journal-title":"Eur Respiratory J"},{"issue":"2","key":"10.1016\/j.jctube.2021.100216_b0085","doi-asserted-by":"crossref","first-page":"1800537","DOI":"10.1183\/13993003.00537-2018","article-title":"QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study","volume":"52","author":"Guglielmetti","year":"2018","journal-title":"Eur Respiratory J"},{"key":"10.1016\/j.jctube.2021.100216_b0090","doi-asserted-by":"crossref","unstructured":"Mase S, Chorba T, Parks S, et al. Bedaquiline for the treatment of multidrug-resistant tuberculosis in the United States. Clin Infect Dis 2020; 71:1010-6.","DOI":"10.1093\/cid\/ciz914"},{"key":"10.1016\/j.jctube.2021.100216_b0095","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"QT Effects of Bedaquiline, Delaminid or Both in MDR-TB patients: The DELIBERATE Trial","author":"Dooley","year":"2019"},{"issue":"7","key":"10.1016\/j.jctube.2021.100216_b0100","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/jce.12976","article-title":"Comparison of QT interval readings in normal sinus rhythm between a smartphone heart monitor and a 12-Lead ECG for Healthy Volunteers and Inpatients Receiving Sotalol or Dofetilide","volume":"27","author":"Garabelli","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"24","key":"10.1016\/j.jctube.2021.100216_b0105","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1161\/CIRCULATIONAHA.119.039598","article-title":"The QT interval","volume":"139","author":"Giudicessi","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jctube.2021.100216_b0110","first-page":"493","article-title":"Circadian rhythm of the signal averaged electrocardiogram and its relation to heart rate variability in healthy subjects","volume":"79","author":"Nakagawa","year":"1998","journal-title":"Heart (British Cardiac Society)"},{"issue":"1","key":"10.1016\/j.jctube.2021.100216_b0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jcph.1283","article-title":"Diurnal profile of the QTc interval following moxifloxacin administration","volume":"59","author":"T\u00e4ubel","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jctube.2021.100216_b0120","unstructured":"Global tuberculosis report 2019. World Health Organization. 2019 Available at: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/329368\/9789241565714-eng.pdf?ua=1."},{"key":"10.1016\/j.jctube.2021.100216_b0125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijid.2019.03.036","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: a global feasibility study","volume":"83","author":"Akkerman","year":"2019","journal-title":"Int J Inf Dis"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240557942100005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240557942100005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:36:56Z","timestamp":1762501016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240557942100005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":25,"alternative-id":["S240557942100005X"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2021.100216","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2021.100216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100216"}}